Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease-Reference-Cited by-同舟云学术

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease

Published:2016-08 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Garcia-Miralles Marta,Hong Xin,Tan Liang Juin,Caron Nicholas S.,Huang Yihui,To Xuan Vinh,Lin Rachel Yanping,Franciosi Sonia,Papapetropoulos Spyros,Hayardeny Liat,Hayden Michael R.,Chuang Kai-Hsiang,Pouladi Mahmoud A.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep31652.pdf

Reference73 articles.

1. Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 15005, 10.1038/nrdp.2015.5 (2015).

2. Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet neurology 12, 637–649 (2013).

3. Wild, E. J. & Tabrizi, S. J. Targets for future clinical trials in Huntington’s disease: What’s in the pipeline? Mov Disord, 10.1002/mds.26007 (2014).

4. Ross, C. A. & Tabrizi, S. J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet neurology 10, 83–98 (2011).

5. Crotti, A. & Glass, C. K. The choreography of neuroinflammation in Huntington’s disease. Trends Immunol 36, 364–373 (2015).

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington’s Disease: A Review of Data from Mouse Models;Journal of Huntington's Disease;2024-09-10

2. Inflammation and Huntington’s disease – a neglected therapeutic target?;Expert Opinion on Investigational Drugs;2024-05-03

3. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study;The Lancet Neurology;2024-03

4. Neuroimmunomodulatory properties of laquinimod;Brain Disorders;2024-03

5. Associations of inflammatory cytokines and cortisol with nonmotor features of Huntington's disease;Annals of Clinical and Translational Neurology;2024-02-14